GURUFOCUS.COM » STOCK LIST » USA » NAS » Enanta Pharmaceuticals Inc (NAS:ENTA) » Definitions » Financial Strength
Switch to:

Enanta Pharmaceuticals Financial Strength

: 8 (As of Jun. 2022)
View and export this data going back to 2013. Start your Free Trial

Enanta Pharmaceuticals has the Financial Strength Rank of 8. It shows strong financial strength and is unlikely to fall into distressed situations.

Good Sign:

Enanta Pharmaceuticals Inc shows strong financial strength.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

GuruFocus does not calculate Enanta Pharmaceuticals's interest coverage with the available data. Enanta Pharmaceuticals's debt to revenue ratio for the quarter that ended in Jun. 2022 was 0.32. As of today, Enanta Pharmaceuticals's Altman Z-Score is 18.24.


Competitive Comparison

For the Biotechnology subindustry, Enanta Pharmaceuticals's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Enanta Pharmaceuticals Financial Strength Distribution

For the Biotechnology industry and Healthcare sector, Enanta Pharmaceuticals's Financial Strength distribution charts can be found below:

* The bar in red indicates where Enanta Pharmaceuticals's Financial Strength falls into.



Enanta Pharmaceuticals Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Enanta Pharmaceuticals's Interest Expense for the months ended in Jun. 2022 was $0.00 Mil. Its Operating Income for the months ended in Jun. 2022 was $-32.54 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was $22.21 Mil.

Enanta Pharmaceuticals's Interest Coverage for the quarter that ended in Jun. 2022 is

GuruFocus does not calculate Enanta Pharmaceuticals's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Enanta Pharmaceuticals Inc has enough cash to cover all of its debt. Its financial situation is stable.

2. Debt to revenue ratio. The lower, the better.

Enanta Pharmaceuticals's Debt to Revenue Ratio for the quarter that ended in Jun. 2022 is

Debt to Revenue Ratio=Total Debt (Q: Jun. 2022 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(2.599 + 22.209) / 77.916
=0.32

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Enanta Pharmaceuticals has a Z-score of 18.24, indicating it is in Safe Zones. This implies the Z-Score is strong.

Good Sign:

Altman Z-score of 18.24 is strong.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enanta Pharmaceuticals  (NAS:ENTA) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Enanta Pharmaceuticals has the Financial Strength Rank of 8. It shows strong financial strength and is unlikely to fall into distressed situations.


Enanta Pharmaceuticals Financial Strength Related Terms

Thank you for viewing the detailed overview of Enanta Pharmaceuticals's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Enanta Pharmaceuticals Business Description

Enanta Pharmaceuticals logo
Traded in Other Exchanges
Address
500 Arsenal Street, Watertown, MA, USA, 02472
Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
Executives
Russell Lesley director 41 MOORES RD. FRAZER PA 19355
Peterson Kristine director AMARIN CORPORATION MYSTIC PACKER BLDG., 12 ROOSEVELT AVENUE MYSTIC CT 06355
Foletta Mark G director AMYLIN PHARMACEUTICALS INC 9360 TOWNE CENTRE DR SAN DIEGO CA 92121
Hata Yujiro S director C/O XENCOR, INC. 111 WEST LEMON AVENUE MONROVIA CA 91016
Luu Brendan officer: Sr. VP, Business Dev. C/O ENANTA PHARMACEUTICALS, INC. 500 ARSENAL STREET WATERTOWN MA 02472
Kieffer Tara Lynn officer: Sr. VP, New Product Dev. C/O ENANTA PHARMACEUTICALS, INC. 500 ARSENAL STREET WATERTOWN MA 02472
Adda Nathalie officer: Sr. VP & Chief Medical Officer C/O ENANTA PHARMACEUTICALS, INC. 500 ARSENAL STREET WATERTOWN MA 02472
Gardiner Nathaniel S. director C/O ENANTA PHARMACEUTICALS, INC. 500 ARSENAL STREET WATERTOWN MA 02472
Golumbeski George director C/O CELGENE CORP. 86 MORRIS AVENUE SUMMIT NJ 07901
Ocain Tim officer: Senior Vice President C/O ENANTA PHARMACEUTICALS, INC. 500 ARSENAL STREET WATERTOWN MA 02472
Carter Bruce L A director C/O ZYMOGENETICS, INC. 1201 EASTLAKE AVENUE SEATTLE WA 98102
Saints Capital Granite, L.p. 10 percent owner 475 SANSOME STREET SUITE 1850 SAN FRANCISCO CA 94111
Saints Capital Granite, Llc 10 percent owner 475 SANSOME STREET, SUITE 1850 SAN FRANCISCO CA 94111
Obp (bermuda) Iii - Holdings Llc 10 percent owner 475 SANSOME STREET, SUITE 1850 SAN FRANCISCO CA 94111
Mrna - Holdings Llc 10 percent owner 475 SANSOME STREET, SUITE 1850 SAN FRANCISCO CA 94111

Enanta Pharmaceuticals Headlines

From GuruFocus

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)